Chisa Yamada1, Daniel S Ramon2, Marilia Cascalho3, Randall S Sung4, Alan B Leichtman5, Milagros Samaniego5, Robertson D Davenport1. 1. Transfusion Medicine Division, Department of Pathology, University of Michigan, Ann Arbor, Michigan. 2. Histocompatibility Lab Division, Department of Pathology, University of Michigan, Ann Arbor, Michigan. 3. Transplant Biology Division, Department of Surgery, Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan. 4. General Surgery Division, Department of Surgery, University of Michigan, Ann Arbor, Michigan. 5. Nephrology Division, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Donor-specific antibodies (DSAs) to HLA antigens can cause acute antibody-mediated rejection (AMR) after kidney transplantation (Txp). Therapeutic plasma exchange (TPE) has been used for AMR treatment; however, DSA reduction rates are inconsistent. We investigated DSA reduction rates by HLA specificity and clinical outcome. STUDY DESIGN AND METHODS: Sixty-four courses of TPE for 56 kidney Txp recipients with high DSA were investigated. Dates of TPE procedures and Txp, patients' age, sex, race, creatinine (Cr), and mean fluorescent intensity (MFI) of DSA were retrieved. MFI reduction rate after one to three TPE and four to six TPE procedures were calculated by HLA DSA specificity in each patient, and the mean reduction rates were compared. The relationship of TPE treatment, MFI or Cr improvement rate, and graft age was also investigated. RESULTS: Patients received a mean 6.0 TPE procedures. Most received intravenous immunoglobulin after TPE and immunosuppressives. Forty-two cases (65.6%) had DSA to HLA Class I and 54 cases (84.4%) to Class II, including 32 cases (50.0%) to both. Mean MFI reduction rates after one to three TPE and four to six TPE procedures were 25.7 and 37.1% in HLA Class I, 25.1 and 34.2% in Class II, and 14.3 and 19.9% in DR51-53. The mean Cr improvements at the end of TPE and 3 and 6 months after TPE were 3.41, -0.37, and -0.72%, respectively. CONCLUSION: Six TPE procedures decreased DSA more than three TPE procedures, but reduction rate was lower by the second three TPE procedures than the first three TPE procedures. Although the mean Cr improvement was minimal, the treatment has good potential to stop further deterioration of kidney function. Better Cr improvement rate is correlated with the graft age.
BACKGROUND:Donor-specific antibodies (DSAs) to HLA antigens can cause acute antibody-mediated rejection (AMR) after kidney transplantation (Txp). Therapeutic plasma exchange (TPE) has been used for AMR treatment; however, DSA reduction rates are inconsistent. We investigated DSA reduction rates by HLA specificity and clinical outcome. STUDY DESIGN AND METHODS: Sixty-four courses of TPE for 56 kidney Txp recipients with high DSA were investigated. Dates of TPE procedures and Txp, patients' age, sex, race, creatinine (Cr), and mean fluorescent intensity (MFI) of DSA were retrieved. MFI reduction rate after one to three TPE and four to six TPE procedures were calculated by HLA DSA specificity in each patient, and the mean reduction rates were compared. The relationship of TPE treatment, MFI or Cr improvement rate, and graft age was also investigated. RESULTS:Patients received a mean 6.0 TPE procedures. Most received intravenous immunoglobulin after TPE and immunosuppressives. Forty-two cases (65.6%) had DSA to HLA Class I and 54 cases (84.4%) to Class II, including 32 cases (50.0%) to both. Mean MFI reduction rates after one to three TPE and four to six TPE procedures were 25.7 and 37.1% in HLA Class I, 25.1 and 34.2% in Class II, and 14.3 and 19.9% in DR51-53. The mean Cr improvements at the end of TPE and 3 and 6 months after TPE were 3.41, -0.37, and -0.72%, respectively. CONCLUSION: Six TPE procedures decreased DSA more than three TPE procedures, but reduction rate was lower by the second three TPE procedures than the first three TPE procedures. Although the mean Cr improvement was minimal, the treatment has good potential to stop further deterioration of kidney function. Better Cr improvement rate is correlated with the graft age.
Authors: Z A Stewart; T E Collins; A J Schlueter; T I Raife; D G Holanda; R Nair; A I Reed; C P Thomas Journal: Transplant Proc Date: 2012-09-06 Impact factor: 1.066
Authors: Jean Kwun; Marie Matignon; Miriam Manook; Soulef Guendouz; Vincent Audard; David Kheav; Elsa Poullot; Chantal Gautreau; Brian Ezekian; Diane Bodez; Thibault Damy; Laureline Faivre; Dehbia Menouch; Janghoon Yoon; Jaeberm Park; Karim Belhadj; Dongfeng Chen; Alyssa M Bilewski; John S Yi; Bradley Collins; Mark Stegall; Alton B Farris; Stuart Knechtle; Philippe Grimbert Journal: J Am Soc Nephrol Date: 2019-06-21 Impact factor: 10.121
Authors: April A Pottebaum; Karthikeyan Venkatachalam; Chang Liu; Daniel C Brennan; Haris Murad; Andrew F Malone; Tarek Alhamad Journal: Transplant Direct Date: 2020-03-13